Trial reportThe Laryngoscope2020
Autologous fibroblasts for vocal scars and age-related atrophy: A randomized clinical trial.
Trial report in The Laryngoscope, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 22 citations in OpenAlex.
- Global Panoramic analysis of clinical research in cell therapy: clinical trial landscape, marketed products, and regulatory trends.Frontiers in pharmacology · 2026Pooled it
- Glottic insufficiency caused by vocal fold atrophy with or without sulcus: systematic review of outcome measurements.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2024Pooled it
- An open phase I/IIa study evaluating safety, patient-reported outcomes and voice function after surgery, local administration of mesenchymal stromal cells and voice training in patients with vocal fold scarring and dysphonia.Stem cell research & therapy · 2026Trial
- Presbylarynx and Laryngeal Asymmetry as Predictors of Dysphonia in Patients 65 and Over.The Laryngoscope · 2026Article
- Regenerative Strategies for Vocal Fold Repair Using Injectable Materials.Biomimetics (Basel, Switzerland) · 2025Review
- 5-Aminolevulinic acid-mediated photodynamic therapy improves scar healing of laryngeal wounds in rats.Lasers in medical science · 2025Article
- Immunocytochemistry assessment of vocal fold regeneration after cell-based implant in rabbits.Laryngoscope investigative otolaryngology · 2024Article
- High-Resolution Profiling of Human Vocal Fold Cellular Landscapes With Single-Nuclei RNA Sequencing.The Laryngoscope · 2024Article
- Cell-Based Outer Vocal Fold Replacement Both Treats and Prevents Vocal Fold Scarring in Rabbits.The Laryngoscope · 2024Article
- Article
- A xenograft study of human adipose stromal cell-based vocal fold mucosal replacement in rabbits.Laryngoscope investigative otolaryngology · 2022Article
- Antifibrotic effects of Quercetin on TGF-β1-induced vocal fold fibroblasts.American journal of translational research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
objectives/hypothesisTo assess the safety and efficacy of autologous cultured fibroblasts (ACFs) to treat dysphonia related to vocal fold scar and age-related vocal atrophy (ARVA). STUDY
designRandomized, double-blinded, placebo-controlled, multi-institutional, phase II trial.
methodsACFs were expanded from punch biopsies of the postauricular skin in each subject; randomization was 2:1 (treatment vs. placebo). Three injections of 1-2 × 10
resultsFifteen subjects received ACF and six received saline injections. At 4, 8, and 12 months after ACF treatments, a significant improvement in mucosal wave grade relative to baseline was observed in both vocal scar and ARVA groups. Relative to control group, mucosal waves were significantly improved in the ARVA group at 4 and 8 months. Perceptual analysis significantly improved in the vocal scar group 12 months after ACF treatments compared to controls. Vocal scar group reported significantly improved vocal quality from baseline. VHI and expert rater voice grade improved in both groups, but did not achieve significance. No adverse events related to fibroblast injections were observed.
conclusionsIn this cohort, injection of ACFs into the vocal fold lamina propria (LP) was safe and significantly improved mucosal waves in patients with vocal scar and ARVA. ACF may hold promise to reconstruct the LP. LEVEL OF EVIDENCE: 1 Laryngoscope, 130:2650-2658, 2020.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.